Stapled RAP12 peptide ligand of LRP1 for micelles-based multifunctional glioma-targeted drug delivery

The RAP12 peptide derived from miniaturization of receptor-associated protein (RAP) holds binding affinity with low-density lipoprotein receptor-related protein-1 (LRP1). However, RAP12 exhibited weak a-helical segments when taken out of the stabilizing protein context. Considering that the alpha-helix is a common structural motif of the peptide to mediate ligand-receptor interactions, we utilized the peptide stapling technique to generate RAP12 with all-hydrocarbon tethers, named stapled RAP12 (ST-RAP12). This optimized ST-RAP12 was verified to obtain an increased a-helical content, binding affinity with LRP1 and serum stability compared to RAP12. In addition, ST-RAP12 exhibited enhanced cellular internalization of bEnd.3 cell, U87 glioma cells and HUVEC. Furthermore, the ability of ST-RAP12 to overcome in vitro BBB/BBTB was also potentiated. Next, ST-RAP12 peptide was further applied to modify polymeric materials to construct ST-RAP12-micelles. It is verified that the ST-RAP12-micelles effectively penetrated BBB/BBTB and targeted glioma in vitro/vivo, and immunofluorescence studies demonstrated its targeting ability to tumor angiogenesis and LRP1. Moreover, ST-RAP12-micelles efficiently delivered paclitaxel (PTX) to glioma, prolonged the survival time of glioma-bearing mice, inhibited tumor angiogenesis and induced glioma apoptosis, which displayed obvious anti-glioma efficacy. Overall, ST-RAP12 is anticipated to be a widely used LRP1-targeted peptide and could be translated as a multifunctional ligand for glioma-targeted drug delivery.

Automated summary

By optimizing the structure and stability of RAP12 peptide, a novel ST-RAP12 peptide was developed with enhanced α-helical content, binding affinity, and cellular internalization, showing promising capabilities in penetrating the blood-brain barrier and targeting glioma. ST-RAP12 was also utilized to construct micelles for effective drug delivery to glioma cells, demonstrating significant anti-cancer efficacy.